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Although most evident in the skin, the process of scarring, or ﬁbrosis, occurs in all major organs because of impaired epithelial
self-renewal. No current therapy exists for Idiopathic pulmonary ﬁbrosis. The major proﬁbrotic factor is TGF-β1 and developing
inhibitors is an area of active research. Recently, IGFBP-5 has also been identiﬁed as a proﬁbrotic factor, and studies suggest
that, while both TGF-β1 and IGFBP-5 activate mesenchymal cells to increase collagen and ﬁbronectin production, their eﬀects
on epithelial cells are distinct. TGF-β1 induces cell death and/or EMT in the epithelial cells, exacerbating the disruption of tissue
architecture. In contrast, IGFBP-5 induces epithelial cell spreading over collagen or ﬁbronectin matrices, increases secretion of
laminin, the epithelial basement membrane, and enhances the survival of epithelial cells in nutrient-poor conditions, as exists in
scar tissue. Thus, IGFBP-5 may enhance repair and may be an important target for antiﬁbrotic therapies.
1.Introduction
Idiopathic Pulmonary ﬁbrosis (IPF) is a nonneoplastic
chronic lung syndrome that is characterized by aberrant
accumulation of ﬁbroblasts/myoﬁbroblasts and progressive
abnormal remodelling of lung parenchyma, with subsequent
scarring and disruption of its structure and function. It
belongs to a broad category of 200 disorders called diﬀuse
pulmonary lung diseases (DPLDs) or simply interstitial lung
diseases (ILDs). This is further classiﬁed into a subgroup
known as idiopathic interstitial pneumonia (IIP), where IPF
is one of the seven diseases, being the most prevalent and
pernicious disorder. It is subclassiﬁed with a pathological
condition known as usual interstitial pneumonia (UIP).
Major symptoms include chronic dyspnea (shortness of
breath) induced by 6-minute walk test, persistent dry cough,
reduced lung volume, and impaired gas exchange. Constitu-
tionalsymptomsincludeweightloss,fatigue,ﬁngerclubbing,
and general malaise [1]. IPF has a poor prognosis and is ﬁve
times more prevalent than cystic ﬁbrosis and amyotrophic
lateral sclerosis, with no FDA approved treatments. Despite
considerable recent progress, current treatment regimens
are largely unpromising with a median survival rate of
less than three years from the date of diagnosis [2]. The
precise mechanisms involved in the pathogenesis of IPF have
not been completely understood. Here, in this paper, we
attempttohighlightthepathologyofpulmonaryﬁbrogenesis
fromitshistory,possiblecellularandmolecularmechanisms,
and draw comparisons between the major proﬁbrotic factor
TGF-β1 and a more recently described player, IGFBP-5.
2. IPFIncidence andPathophysiology
IPF is usually a disease of the elderly and occurs after ﬁve
decades of life, with the probability of incidence markedly
increasing thereafter. The onset of disease is slow but
with age and time, the symptoms increase. There are ﬁve
million suﬀerers, with increasing world-wide incidence, that
are aﬀected by IPF [3]. The number of aﬀected patients
has doubled in the past decade [4] and inevitably will
increase in developed countries due to increasing age of the
population. The disease is slightly more prevalent in men [5]
and strongly associated with cigarette smoking [6]. Recent
statistics of large United States and UK population-based
studies indicated a signiﬁcant increase in mortality [7, 8].2 Pulmonary Medicine
Annually, 40,000 and 4,000 new cases were diagnosed each
year in US and UK, respectively.
Pulmonary ﬁbrosis can also occur due to a variety of
stimuli ranging from life style habits such as cigarette smok-
ing [6], occupational exposure to polluted environments,
notably asbestos or silica [9], induced by pharmacological
agents [10], radiation exposure [11], and genetic predisposi-
tion [5], or associated with other autoimmune abnormalities
such as collagen vascular diseases [12, 13].
3.EpithelialCellInjuryandIPF
The complex signalling mechanisms of pulmonary epithelial
cell injury in response to ﬁbrosis are of considerable research
interest. As intact alveolar epithelium is critical for main-
taining lung homeostasis, initiation of repair mechanisms
following the insult and injury, without compromising
its structure and function, is of great importance. Our
understanding of the relationship between injury of epithelia
and development of IPF has increased dramatically in recent
years. Current hypotheses suggest that microrepetitive injury
to pulmonary epithelial cells results in ineﬀective repair
with subsequent ﬁbrogenesis. As previously mentioned,
the sources of recurrent injury could be wide ranging
and include toxic or drug-induced insults, autoimmune
disease, traumatic or hypoxic injuries, and bacterial or viral
infections. Recently, a high occurrence of Epstein Barr Virus
(EBV) expressing latent membrane protein (LMB-1) has
been reported in IPF patients with synergizing eﬀects with
TGF-β-induced EMT in lung epithelial cells [14]. Observa-
tions suggest that the release of soluble growth factors after
injury including chemokines, eicosanoids, and interleukins
has also shown to be involved in the resolution of epithelial
repair processes. However, there may be compromise with
respecttostructureandfunctionalorganisationwithvarying
degree of injuries.
4. The Role of Fibroblasts/Myoﬁbroblasts
inIPF
Eﬀective therapies to prevent tissue ﬁbrosis require a com-
plete understanding of the mechanisms involved in the
developmentofthedisease,andonemechanismofparticular
interest is ﬁbroblast development. Resident ﬁbroblasts and
resident activated ﬁbroblasts (myoﬁbroblasts) are critical cell
types for the process of wound healing and also for the for-
mation of ﬁbrotic lesions in the pathogenesis of lung ﬁbrosis.
Fibroblasts express receptors for a number of cytokines
including PDGF [15], TGF-β1[ 16], and TNF-α [16]. These
cytokines and others may mediate their recruitment and
activation during injury. In addition to their involvement
in skin wound healing [17–19], myoﬁbroblasts are most
commonly identiﬁed and well characterized in idiopathic
pulmonary ﬁbrosis [20]. Myoﬁbroblasts are mesenchymal
cells with characteristics of both ﬁbroblasts and smooth
muscle cells [21]. The origin of myoﬁbroblasts is still under
debate. However, persistence of ﬁbroblasts/myoﬁbroblasts at
the site of injury and extracellular matrix (ECM) are critical
for ﬁbrotic lesion formation in IPF [22]. Thus, understand-
ingthemechanismofthegradualdecreaseofmyoﬁbroblasts,
as occurs in normal wound healing, should be important for
the resolution of pulmonary ﬁbrosis.
5. Epithelialto Mesenchymal Transition
EMT is a prominent manifestation of cell plasticity observed
in three distinct cellular processes: embryonic develop-
ment, metastasis, and ﬁbrosis. Here, as per the context,
determination of the cellular source of myoﬁbroblasts is
crucial in understanding the pathogenesis of tissue ﬁbrosis.
Myoﬁbroblasts appear to have at least three possible origins.
Alveolar epithelial damage with consequent EMT, activation
of ﬁbroblasts, and circulating ﬁbrocytes occur through
detection of injurious signals including TGF-β, platelet-
derived growth factor (PDGF), IL-13, and connective tissue
growthfactor(CTGF).Thisresultsinthetransdiﬀerentiation
of myoﬁbroblasts, with smooth muscle actin, MMP-2 and
MMP-9 expression, and excessive collagen production [20].
Resident ﬁbroblasts can respond to a variety of proﬁbrotic
mediators and diﬀerentiate into myoﬁbroblasts [23]. TGF-
β1 induces transdiﬀerentiation of ﬁbroblasts, through a
Smad3-dependent mechanism, to myoﬁbroblasts [24]. In
vivooverexpressionofIGFBP-5inducesincreasedexpression
of α-SMA and vimentin in dermal and lung ﬁbroblasts
suggesting ﬁbroblast transdiﬀerentiation [25, 26].
Epithelial-myoﬁbroblast transdiﬀerentiation from epi-
thelial cells is a specialized version of epithelial-mesen-
chymal transition (EMT), a physiological process in which
epithelial cells can acquire the invasive and motile properties
of mesenchymal cells [27]. Alveolar epithelial cells have been
shown to undergo EMT in vivo during the development
of pulmonary ﬁbrosis [28]. There is also compelling evi-
dence suggesting EMT in alveolar epithelial cells following
exposure to TGF-β both in vitro and in vivo [29–31]. In
addition, circulating bone marrow-derived ﬁbrocytes behave
like mesenchymal stem cells and migrate into sites of lung
injury and become myoﬁbroblasts. These ﬁbrocytes express
type 1 collagen and α-SMA and contribute to lung ﬁbrosis
[32]. It is interesting to note that TGF-β1-induced EMT
is reversed by ﬁbroblast growth factor-1, through ERK
phosphorylation and Smad2 dephosphorylation [33]. This
implies that the therapeutic role of FGF-1 should be deﬁned
in IPF, as inhibiting TGF-β globally may have adverse eﬀects
on its role in tissue homeostasis.
6.ExtracellularMatrix andIPF
Thereisnowmountingevidencesuggestingthatextracellular
matrix (ECM) is involved in both normal physiology as
well as in wide variety of pathophysiological processes.
One possible mechanism of pulmonary ﬁbrosis is the
disruption of ECM which enables cell-to-cell contact of
epithelial cells with ﬁbroblasts, leading to the epithelial cell
inductionofﬁbroblast-andmyoﬁbroblast-derivedsignalling
molecules. The end process of EMT is the degradation
of underlying extracellular matrix with the formation ofPulmonary Medicine 3
additionalmesenchymalcells.Epithelialcellinjurycausesthe
release of a wide variety of growth factors, chemokines and
MMPs, notably MMP-2, MMP-3, and MMP-9, interleukins,
and prostaglandins. Under the inﬂuence of these signalling
molecules,epithelialcells,actingtogetherwithinﬂammatory
cells, induce basement membrane disruption and focal
degradation of type IV collagen and laminin [34].
7. Role of TGF-β inIPF
Transforming growth factor beta (TGF-β) is a pleiotropic
regulatory cytokine that is ubiquitously expressed by all
cells and tissues within the body. TGF-β1, of the three
highly homologous mammalian isoforms (TGF-β1-3), is
thought to play a central mediator role in wound healing
and ﬁbrosis [35–37]. There is compelling evidence that TGF-
β1 plays a pivotal role in pathophysiology of IPF. There is
increasing evidence pointing to the proﬁbrogenic eﬀects of
TGF-β both in animal models of IPF and in IPF patients.
Induction of EMT in alveolar epithelial cells following
TGF-β1 overexpression in triple transgenic mice and via
adenoviral-mediatedgenetransferinducesseverepulmonary
ﬁbrosis. In contrast, ex vivo alveolar epithelial cells cultured
on laminin/collagen mixtures undergo programmed cell
death when exposed to active TGF-β [28].
8.Integrin-MediatedActivationof TGF-β
The integrins are a large family of transmembrane het-
erodimeric cell adhesion receptors which mediate cell-
to-surface interactions either to the extracellular cellular
matrix or to speciﬁc cell-surface receptors during cell-cell
interactions [38, 39]. They are composed of α and β dimers
in a noncovalent complex, comprising 24 combinations of
18 α and 8 β subunits. These receptors function as important
regulatorsthatcontrolwholesetsofcellularprocessesinclud-
ing cell spreading, retraction, migration, and proliferation.
Integrins contain the specialized binding regions for physical
attachment of cells to the ECM, and through intracellular
domains they form connections to various components of
the actin cytoskeleton and a wide variety of interconnecting
signalling adaptors [40].
The cross talk between integrins and TGF-β signalling is
of considerable interest in a wide variety of physiological and
pathophysiological processes including ﬁbrosis, cancer, and
wound healing. The molecular interactions between TGF-β
and integrins αVβ6a n dαVβ8 are of particular interest in the
pathogenetic mechanisms of pulmonary ﬁbrogenesis. The
αVβ6 integrin-dependent activation of TGF-β requires the
binding of the β6 cytoplasmic tail to the actin cytoskeleton
[41]. This activation of TGF-β is highly dependent on the
association of inactive (latent) forms of TGF-β and TGF-
β binding protein-1 (LTBP-1) of the large latent complex
with αVβ6 integrin [42]. Furthermore, lysophosphatidic
acid and stimulation of protease-activated receptor 1 have
shown to activate αVβ6-mediated activation of TGF-β1v i a
RhoA and are implicated in the pathogenensis of acute lung
injury and pulmonary ﬁbrosis [43, 44]. Partial inhibition of
αVβ6 integrin-mediated activation of TGF-β1 using small
molecule inhibitors has been shown to possess antiﬁbrotic
activity, without pulmonary inﬂammation and emphysema
[45].
9. Role of IGFBP-5 in IPF
IGFBP-5 is one of the members of insulin-like growth-
factor-binding protein (IGFBP) family which bind to and
modulate the biological actions of insulin-like growth fac-
tors by interference with receptor binding although these
IGFBPs also have IGF-independent actions [46]. Increased
expression of IGFBP-5 has been described in ﬁbrosis [47,
48]. Increased expression of IGFBP-5 at mRNA and protein
levels was also evident in vitro in primary ﬁbroblasts
cultured from disease-aﬀected skin of patients with systemic
sclerosis/scleroderma, compared with the skin from their
healthy twins. It has been demonstrated that IGFBP-5
inducescollagenandﬁbronectinproductionfromﬁbroblasts
and induces ﬁbroblast/myoﬁbroblast transdiﬀerentiation in
vitro and in vivo [25, 26]. Finally, in vivo overexpression
of IGFBP5, using replication-deﬁcient adenovirus, induced
skin ﬁbrosis in mice which included increased thickness of
the dermis and increased collagen bundle thickness [25]a n d
induced pulmonary ﬁbrosis with myoﬁbroblastic changes
[26]. Increased expression of α- S M Aa n dvi m e n t i ni nd e rm a l
ﬁbroblasts was also evident with overexpression of IGFBP-
5. Collectively, these ﬁndings suggest that upregulated
expression of IGFBP5 could be an initiating event in ECM




Integrin αVβ6 expression is constitutively expressed at low
levelsinepithelialtissuesandwassigniﬁcantlyincreaseddur-
inginjurybutwasunabletopotentiateﬁbrosis[49].Recently,
we demonstrated that αVβ6 integrin is also essential in
addition to α2a n dβ1 integrins for the IGFBP-5-induced
cell to extracellular matrix adhesion in MCF-7 cells. Using
biosensortechnology,weshowedanovel,direct,highaﬃnity
interaction of IGFBP-5 with α2a n dβ1 integrins leading
to the activation of ILK and Akt and improved epithelial
cell adhesion and survival (our unpublished observations).
Apoptosis of epithelial cells induces IGFBP-5 which activates
tissue plasminogen activator (tPA), generating plasmin, and
also interacts with several matricellular proteins [50]. Thus,
IGFBP-5 may act as a central mediator in the initial response
of epithelial cell injury.
This provides an intriguing possibility in which IGFBP-
5 acts indirectly, extracellularly, in a similar fashion to
connective tissue growth factor (CTGF), which also serves
as a mediator of the actions of TGF-β1[ 51]. CTGF is
structurally related to IGFBP-5 and interacts with integrins
to elicit its actions, rather than using classic cell-surface
receptors. In fact, there are similarities between IGFBP-5 and
other members of the secreted cysteine-rich (CCN) protein4 Pulmonary Medicine
family which includes CTGF, CYR61, and Nov. The CCN
molecules were temporarily renamed IGFBP8-10 because of
theirstructuralrelationshipwiththeIGFBPfamily.However,
webelievethatIGFBP-5maybeamemberoftheCCNfamily
since it binds and activates integrins, interacts with the ECM
via a heparin-binding domain, and inﬂuences growth factor
actions (IGFs) indirectly by binding to them. In analogous
fashion, CTGF as well as binding to integrins and the ECM
binds to VEGF [52] to inhibit its actions and bind to, and
enhances the actions of, TGF-β1[ 53].
The adhesive responses to IGFBP-5 could be anticipated
to enhance re-epithelialisation during injury by increasing
the surface area of epithelial cells when epithelia are exposed
to a mesenchymal environment, whilst concurrently inhibit-
ing their migration into the mesenchymal compartment.
Thus, IGFBP-5 would be anticipated to display antagonistic
actions to TGF-β1 in the epithelial compartment whilst
enhancing its actions in the mesenchymal compartment
(Figure 1).
11. TGF-β and IGFBP-5:Redundancy or
Complementarity of Actions?
The recent studies implicating IGFBP-5 in the development
of ﬁbrosis begs the question “Do TGF-β1 and IGFBP-5
serve similar roles and, if so, why? We believe that, although
their roles in the mesenchymal compartment are similar
and certainly complementary, their actions in the epithelial
compartment are diﬀerent. Whereas TGF-β1i sc l e a r l y
apoptotic and induces EMT in a proportion of the epithelial
cells, thus disrupting the epithelial compartment and its
functions both as a physical barrier and in, for example,
gas exchange in the lung, the actions of IGFBP-5 are quite
distinct. We have shown that IGFBP-5 induces an adhesive
action[50]inepithelialcellsexposedtoamesenchymalenvi-
ronment, leading to increased cell spreading and decreased
migration and propose that this serves as a mechanism to
prevent epithelial egress from, and mesenchymal ingress
into, the epithelial compartment. IGFBP-5 also increases
epithelial production of the basement membrane protein,
laminin [54]. These actions would be anticipated to limit
the boundary of the ﬁbrotic response to the underlying
stroma. Thus, IGFBP-5 may be a more relevant target in
therapies of wound repair than TGF-β1, since it enhances
ﬁbrosis but limits scar formation to the mesenchymal
compartment, thereby preventing excessive disruption of the
epithelium. This contrasts with the uncontrolled ﬁbrotic
response characteristically produced by TGF-β1.
12. ClinicalImplications
Fibrotic diseases in general, and idiopathic pulmonary
ﬁbrosis in particular, represent disease states for which no
therapies currently exist. Targeting the major ﬁbrotic agents
may provide the prospect of developing such therapies,
and TGF-β1 is, indeed, the target of research programmes
seeking pharmacological inhibitors. The complementary



























Figure 1:DiﬀerentialeﬀectsofTGF-β1andIGFBP -5onmese nc h y-
mal and epithelial cells. In ﬁbroblasts, TGF-β1 activates the Smad
pathwayresultinginactivationofgenesassociatedwithﬁbrosissuch
as collagen, ﬁbronectin, and CTGF. CTGF in turn further activates
this process via an aVb3 integrin-dependent mechanism. IGFBP-5
binds to and activates α2β1 integrins and is capable of activating
MAPK pathways in similar fashion to CTGF. In contrast, TGF-β1
activation of the Smad pathway results in an apoptotic pathway
in epithelial cells, whereas IGFBP-5, again acting through α2β1
integrin,stimulatesanadhesive,prosurvivalpathway.Thus,IGFBP-
5 enhances TGF-β1 actions in the mesenchymal compartment but
inhibits them in the epithelium.
provide additional options for drug targets although a better
understanding of their precise mechanisms of action will be
essential to enhance the prospects of success. Nevertheless,
the potential protective role of IGFBP-5 in the epithelium
is particularly amenable to aerosol-mediated drug delivery
systems, since this would provide direct access to the site
of action required for eﬀective re-epithelialisation to occur.
Possible approaches could include smaller domains of the
IGFBP-5molecule,whichcanexerttheseeﬀects,drugswhich
mimic its adhesive, survival eﬀects, or drugs, such as retinoic
acid and vitamin D analogues, that are known to stimulate
its production in epithelial cells [55–57].Pulmonary Medicine 5
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